What happens when natalizumab therapy is stopped?

Expert Review of Neurotherapeutics

Volumn 11, Issue 9, 2011, Pages 1247-1250

  Schaaf, Stephen M ^a   Pitt, David ^a   Racke, Michael K ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB; PLACEBO;

CLINICAL FEATURE; DISEASE ACTIVITY; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW;

EID: 80052211632     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.109     Document Type: Review

References (18)

1. Frohman, EM, Racke MK, Raine CS. Multiple sclerosis: The plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006). . Excellent overview of the pathogenesis of multiple sclerosis (MS).
2. Warnke C, Menge T, Hartung HP et al. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided? Arch. Neurol. 67, 923-930 (2010).
3. Sandrock AW, Hotermans C, Richman S et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. Int. J. MS Care 13(Suppl. 3), 53-54 (2011).
4. Miravalle A, Jensen R, Kinkel R. Immune reconstitution syndrome in multiple sclerosis patients following cessation of natalizumab therapy. Arch. Neurol. 68(2), 186-191 (2011).
5. Stüve O, Marra CM, Bar-Or A et al. Altered CD4+/CD8+ T cells ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch. Neurol. 63, 1383-1387 (2006). (Pubitemid 44547548)
6. Stüve O, Marra CM, Jerome KR et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59, 743-747 (2006). .. Study that showed that immune cells were present in the cerebrospinal fluid of natalizumab-treated MS patients at much lower levels than either untreated MS patients or patients with other noninflammatory neurological disorders. (Pubitemid 43673151)
7. Gorelik L, Reid C, Testa M et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein vp1 that change its receptor specificity. J. Infect. Dis. 204(1), 103-114 (2011).
8. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003). (Pubitemid 36026342)
9. Stüve O, Cravens PD, Frohman EM et al. Immunological and clinical status 14 months after cessation of natalizumab therapy. Neurology 72 (5), 396-401 (2009).
10. Vellinga MM, Castelijns JA, Barkhof F et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70, 1150-1151 (2008). (Pubitemid 351464749)
11. West TW, Cree BAC. Natalizumab dosage suspension: Are we helping or hurting? Ann. Neurol. 68, 395-399 (2010).
12. O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76(22), 1858-1865 (2011).
13. Khatri BO, Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72, 402-409 (2009).
14. del Pilar Martin M, Cravens PD, Winger R et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 65, 1596-1603 (2008).
15. Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann. Neurol. 68, 295-303 (2010).
16. Polman CH, O'Connor P, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899 -910 (2006). . Phase III clinical trial that resulted in the US FDA approval of natalizumab for the treatment of relapsing-remitting MS.
17. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon b-1 for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923 (2006).
18. Goodman AD, Rossman HS, Bar-Or A et al. GLANCE: Results of a Phase 2, randomized, doubleblind, placebo-controlled study. Neurology 72, 806-812 (2009).